What is ImmunityBio, Inc. (IBRX) stock price today?

ImmunityBio, Inc. (IBRX) is currently trading at $9.91, up 1.64% today.

What is IBRX P/E ratio?

ImmunityBio, Inc.'s P/E ratio is -10.01. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IBRX return on equity (ROE)?

ImmunityBio, Inc.'s return on equity (ROE) is 134.99%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is ImmunityBio, Inc.'s market cap?

ImmunityBio, Inc. has a market capitalization of $10.38B.

NASDAQ · Biotechnology

ImmunityBio, Inc. (IBRX) Stock

$9.91 +1.64% NASDAQ: IBRX Healthcare

Valuation

Metric	Value
Price	$9.91
Market Cap	$10.38B
P/E Ratio	-10.01
P/B Ratio	-9.78
P/S Ratio	61.59
EPS (TTM)	$-0.85
52-Week High	$12.43
52-Week Low	$1.95
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	134.99%
ROA	-157.89%
ROCE	-45.63%
Gross Margin	99.34%
Operating Margin	-1.58%
Net Margin	-598.56%
Debt/Equity	-0.78
Current Ratio	6.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$0	$1.0M	$15.0M	$113.0M
Operating Profit	$-330.0M	$-351.0M	$-362.0M	$-344.0M	$-256.0M
Net Profit	$-347.0M	$-417.0M	$-583.0M	$-414.0M	$-351.0M
EPS	$-0.89	$-1.04	$-1.15	$-0.62	$-0.38
Op Margin	-35361.9%	-146374.2%	-58239.6%	-2334.2%	-226.0%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$469.0M	$362.0M	$504.0M	$383.0M	$502.0M
Total Liabilities	$713.0M	$812.0M	$1.1B	$871.0M	$1.0B
Cash	$181.0M	$105.0M	$265.0M	$143.0M	$88.0M
Borrowings	$646.0M	$724.0M	$727.0M	$504.0M	$878.0M

Latest News

IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst Stocktwits · Jul 14, 2026 Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout 24/7 Wall St. · Jul 10, 2026 Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise Stocktwits · Jul 10, 2026 ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing MT Newswires · Jul 7, 2026 ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing MT Newswires · Jul 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-274.0M	$-338.0M	$-367.0M	$-391.0M	$-305.0M
Investing Cash Flow	$-118.0M	$-51.0M	$-61.0M	$-19.0M	$-154.0M
Financing Cash Flow	$167.0M	$60.0M	$-3.0M	$73.0M	$-2.0M
Net Cash Flow	$146.0M	$-76.0M	$161.0M	$-122.0M	$-54.0M
Free Cash Flow	$-308.0M	$-416.0M	$-397.0M	$-398.0M	$-309.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.08
EV / EBITDA	-12.33
FCF Yield	-2.83%
Quick Ratio	5.70
Interest Coverage	-3.02
Return 1Y	283.00%
Return 3Y	582.39%
Return 5Y	-0.10%

Ownership

Insiders Held62.47%

Institutions Held17.66%

Institutions Float Held47.05%

Institutional Holder	Shares	Report Date
Blackrock Inc.	26,346,443	2026-03-31
State Street Corporation	17,708,103	2026-03-31
Vanguard Portfolio Management LLC	16,322,844	2026-03-31
Vanguard Capital Management LLC	15,127,714	2026-03-31
Shaw D.E. & Co., Inc.	12,571,597	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLOAllogene Therapeutics, Inc.	$1.40	-2.10%	-2.24	$483.22M	0.00%
ATRAAtara Biotherapeutics, Inc.	$9.23	-1.49%	-7.94	$83.16M	0.00%
BNTXBioNTech SE	$90.07	-1.55%	-15.45	$22.78B	0.00%
IMCRImmunocore Holdings plc	$31.95	-3.42%	-85.34	$1.62B	0.00%
IMTXImmatics N.V.	$7.37	-1.07%	-4.33	$988.29M	0.00%

About ImmunityBio, Inc.

ImmunityBio, Inc. is led by CEO Richard Gerald Adcock, employs 691 people, headquartered in San Diego, US, publicly traded since 2015.

ImmunityBio, Inc. (IBRX) stock trades at $9.91 with a market capitalization of $10.38B. The stock is valued at a price-to-earnings (P/E) ratio of -10.01, price-to-book of -9.78, price-to-sales of 61.59. Over the past 52 weeks the stock has ranged between $1.95 and $12.43, and currently trades 20.3% below its 52-week high.

On profitability, ImmunityBio, Inc. generates a return on equity (ROE) of 134.99% — well above the market average, a sign of a high-quality business, return on capital employed of -45.63%, an operating margin of -1.58%, a net profit margin of -598.56%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides